Business
SOPHiA GENETICS Expands Relationship with Gustave Roussy
Gustave Roussy uses SOPHiA DDM™ Platform to empower confident, data-driven medicine in the fight against cancer BOSTON and ROLLE, Switzerland, Aug. 22, 2023
About this update from Sophia Genetics Sa
[{"type":"text","content":"Gustave Roussy uses SOPHiA DDM™ Platform to empower confident, data-driven medicine in the fight against cancer\nBOSTON and ROLLE, Switzerland, Aug. 22, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the expansion of its relationship with Gustave Roussy, the leading cancer center in Europe. With the expanded relationship SOPHiA GENETICS will now further support Gustave Roussy via the SOPHiA DDM™ Platform, which will provide expedited analysis and insights of genomic profiles.\n\n \n \n \n \n \n \n\n \nGustave Roussy is considered among the top 3 specialized hospitals in the world. The institute treats patients of all ages and types of cancer and is an expert in the treatment of rare and complex tumors. With a vision to expand the limits of knowledge and offer patients personalized treatment, the institute began working with SOPHiA GENETICS in 2017 and recently expanded its use of SOPHiA GENETICS technology after a public tender. Gustave Roussy will now utilize the SOPHiA DDM™ Platform for all relevant samples, including those related to solid tumors, hematologic and hereditary cancers.\n\"With the rapidly evolving field of clinical genomics, the challenges of data analysis are now twofold – the ability to meet the production quality requirements, which are becoming more and more stringent with the IVDR regulations, and the ability to innovate with the arrival of new genomic signatures and techniques. The SOPHiA DDM™ Platform, a recognized solution in terms of quality – ISO13485 and ISO27001 - and performance, was the optimal solution for Gustave Roussy,\" said Etienne Rouleau, Head of Genetics Unit at Gustave Roussy.\nThe development of treatment plans for patients with cancer requires institutions to consider an enormous amount of data, which is both time intensive and costly. The expanded use of SOPHiA GENETICS by Gustave Roussy will allow the institute to accelerate diagnostics, and thus the development of cancer treatment plans via optimized workflows that aid clinicians in more quickly drawing meaningful insights from medical data.\n\"SOPHiA GENETICS is uniquely positioned to facilitate the analysis of clinical, biological, and genomics data to provide real-world insights on tumor-driving mutations, variant an...